Thumbnail Image
Item

Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine

Lin, Yi-Jiun
; 
Lin, Meei-Yun
; 
Chuang, Ya-Shan
; 
Liu, Luke Tzu-Chi
; 
Kuo, Tsun-Yung
; 
Chen, Charles
; 
Ganesan, Shyamala
; 
Fattom, Ali
; 
Bitko, Vira
; 
Lien, Chia-En
Citations
Altmetric:
Genre
Journal article
Date
2022-07-05
Advisor
Committee member
Group
Department
Biology
Subject
Drug discovery
 Immunology
 Microbiology
Permanent link to this record
http://hdl.handle.net/20.500.12613/8077
Collections
COVID-19 Research
Show all metadata
Files
Thumbnail Image
Chen-JournalArticle-2022.pdf
Adobe PDF, 1.64 MB
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1038/s41598-022-15238-y
Abstract
Intramuscular vaccines have greatly reduced hospitalization and death due to severe COVID-19. However, most countries are experiencing a resurgence of infection driven predominantly by the Delta and Omicron variants of SARS-CoV-2. In response, booster dosing of COVID-19 vaccines has been implemented in many countries to address waning immunity and reduced protection against the variants. However, intramuscular boosting fails to elicit mucosal immunity and therefore does not solve the problem of persistent viral carriage and transmission, even in patients protected from severe disease. In this study, two doses of stabilized prefusion SARS-CoV-2 spike (S-2P)-based intramuscular vaccine adjuvanted with Alum/CpG1018, MVC-COV1901, were used as a primary vaccination series, followed by an intranasal booster vaccination with nanoemulsion (NE01)-adjuvanted S-2P vaccine in a hamster model to demonstrate immunogenicity and protection from viral challenge. Here we report that this vaccination regimen resulted not only in the induction of robust immunity and protection against weight loss and lung pathology following challenge with SARS-CoV-2, but also led to increased viral clearance from both upper and lower respiratory tracts. Our findings showed that intramuscular MVC-COV1901 vaccine followed by a booster with intranasal NE01-adjuvanted vaccine promotes protective immunity against both viral infection and disease, suggesting that this immunization protocol may offer a solution in addressing a significant, unmet medical need for both the COVID-19 and future pandemics.
Description
Citation
Lin, YJ., Lin, MY., Chuang, YS. et al. Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine. Sci Rep 12, 11369 (2022). https://doi.org/10.1038/s41598-022-15238-y
Citation to related work
Nature Research
Has part
Scientific Reports, Vol. 12
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Embedded videos